The University of Calgary is collaborating with Enveric Biosciences to establish a clinical trial focused on cancer-related distress (CRD) and EVM-101, a psilocybin-based drug.
A systematic review published in Psychopharmacology last year examined 33 articles focused on both classical and atypical psychedelics and concluded that both classifications of drugs offer promising treatment options in patients facing terminal illness.
Researchers wrote that recent controlled trials with LSD, psilocybin, ketamine, and MDMA “indicate positive effects on existential and spiritual well-being, quality of life, acceptance, and reduction of anxiety and depression with few adverse and no serious adverse effects.”
“With the rising rates of cancer and its associated psychological ailments that have been underestimated and underdiagnosed until recently, we are working hard to develop new treatments that help cancer patients suffering from CRD” said Dr. Bob Dagher, Enveric’s Chief Medical Officer. “Our collaboration with the research team
Read full article on The Growth Op
